| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 24/04/2024 | 22:01 | GlobeNewswire Inc. | Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 17/04/2024 | 02:01 | GlobeNewswire Inc. | Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316 | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 10/04/2024 | 14:00 | GlobeNewswire Inc. | Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistanc | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 09/04/2024 | 13:00 | GlobeNewswire Inc. | Acrivon Therapeutics Announces $130 Million Private Placement Financing | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 28/03/2024 | 13:00 | GlobeNewswire Inc. | Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 06/03/2024 | 22:32 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 06/03/2024 | 22:29 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 05/03/2024 | 22:30 | GlobeNewswire Inc. | Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316 | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 04/03/2024 | 14:15 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 04/03/2024 | 14:00 | GlobeNewswire Inc. | Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 27/02/2024 | 14:00 | GlobeNewswire Inc. | Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 13/02/2024 | 21:40 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 08/02/2024 | 14:00 | GlobeNewswire Inc. | Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of Directors | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 06/02/2024 | 14:00 | GlobeNewswire Inc. | Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 12/01/2024 | 22:00 | GlobeNewswire Inc. | Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 04/01/2024 | 14:00 | GlobeNewswire Inc. | Acrivon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 18/12/2023 | 06:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 01/12/2023 | 22:35 | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of 1933 | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 28/11/2023 | 14:58 | Dow Jones News | Acrivon Therapeutics Gets FDA's Breakthrough Designation for Cancer Assay | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 28/11/2023 | 14:00 | GlobeNewswire Inc. | Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Ovarian Cancer | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 21/11/2023 | 14:00 | GlobeNewswire Inc. | Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 21/11/2023 | 14:00 | GlobeNewswire Inc. | Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 09/11/2023 | 14:02 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 09/11/2023 | 14:01 | GlobeNewswire Inc. | Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 16/10/2023 | 14:00 | GlobeNewswire Inc. | Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 19/09/2023 | 22:32 | GlobeNewswire Inc. | Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on Mo | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 05/09/2023 | 22:05 | GlobeNewswire Inc. | Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon’s AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 30/08/2023 | 14:00 | GlobeNewswire Inc. | Acrivon Therapeutics to Participate in Two Investor Conferences in September | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 11/08/2023 | 14:25 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 11/08/2023 | 13:00 | GlobeNewswire Inc. | Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights | NASDAQ:ACRV | Acrivon Therapeutics Inc |